Interestingly, both HLA-A*0201 and PD-L1 expressions increased on SARC-L1 after IFN-γ exposure in vitro defining this tumor very sensitive to several drugs commonly used to treat sarcoma and susceptible to anti-PD-L1 mAb therapy in vivo [222]. The gene discussed is HLA-A; the disease is neoplasm.